Raghunathan Vikram, Zilberman-Rudenko Jevgenia, Olson Sven R, Lupu Florea, McCarty Owen J T, Shatzel Joseph J
Division of Hematology-Medical Oncology Knight Cancer Institute Oregon Health & Science University Portland Oregon USA.
Department of Biomedical Engineering Oregon Health & Science University Portland Oregon USA.
Res Pract Thromb Haemost. 2019 May 23;3(3):331-339. doi: 10.1002/rth2.12217. eCollection 2019 Jul.
The contact pathway factors XI (FXI) and XII (FXII) have been demonstrated to be largely dispensable for hemostasis, as their absence results in a mild to absent bleeding diathesis. A growing body of literature, however, suggests that the contact pathway contributes to the pathologic host response to certain infectious organisms that produces the often-fatal syndrome known as sepsis. The contact pathway factors serve as a central node connecting inflammation to coagulation, and may offer a potentially safe therapeutic target to mitigate the morbidity and mortality associated with sepsis. Herein, we summarize published in vivo and in vitro data that have explored the roles of the contact pathway in sepsis, and discuss potential clinical applications of novel FXI- and FXII-inhibiting drugs currently under investigation.
已证明接触途径因子XI(FXI)和XII(FXII)在很大程度上对于止血并非必需,因为它们的缺乏只会导致轻度至无出血素质。然而,越来越多的文献表明,接触途径会促使宿主对某些感染性生物体产生病理性反应,从而引发通常致命的综合征,即脓毒症。接触途径因子是连接炎症与凝血的核心节点,可能为减轻脓毒症相关的发病率和死亡率提供一个潜在的安全治疗靶点。在此,我们总结了已发表的体内和体外数据,这些数据探讨了接触途径在脓毒症中的作用,并讨论了目前正在研究的新型FXI和FXII抑制药物的潜在临床应用。